Nxera Pharma Co., Ltd. has announced that its product vamorolone has been granted both Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation by the Ministry of Food and Drug Safety (MFDS) in South Korea. These designations are critical for accelerating the regulatory review process for vamorolone, a treatment for Duchenne muscular dystrophy (DMD), a rare disease affecting primarily males. The ODD recognizes DMD as a condition with significant unmet medical needs and no available treatments in South Korea. The GIFT designation allows for a potentially expedited review timeline, reducing the standard 120 working days to as few as 90 days, facilitating quicker patient access to innovative therapies. Nxera plans to submit a Marketing Authorization Application for vamorolone in 2026. Clinical studies have demonstrated that vamorolone significantly improves muscle function while presenting a favorable safety profile compared to traditional corticosteroids. The company emphasizes its commitment to collaborating with regulatory authorities to expedite access for patients suffering from DMD.